Synthetic lethality and cancer

Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions

(2017) Kyuho Han et al.   NATURE BIOTECHNOLOGY

Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions

(2017) John Paul Shen et al.   NATURE METHODS

Pooled CRISPR screening with single-cell transcriptome readout

(2017) Paul Datlinger et al.   NATURE METHODS

Consensus on precision medicine for metastatic cancers: a report from the MAP conference: Table 1.

(2016) C. Swanton et al.   ANNALS OF ONCOLOGY

Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs

(2016) Mark Wappett et al.   BMC GENOMICS

A Landscape of Pharmacogenomic Interactions in Cancer

(2016) Francesco Iorio et al.   CELL

Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq

(2016) Diego Adhemar Jaitin et al.   CELL

Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens

(2016) Atray Dixit et al.   CELL

A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response

(2016) Britt Adamson et al.   CELL

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

(2016) Alejandra Bruna et al.   CELL

Drugging the addict: non‐oncogene addiction as a target for cancer therapy

(2016) Remco Nagel et al.   EMBO REPORTS

A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells

(2016) R. J. D. Reid et al.   GENETICS

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

(2016) Petra ter Brugge et al.   JNCI-Journal of the National Cancer Institute

A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy

(2016) Rohith Srivas et al.   MOLECULAR CELL

Reproducible pharmacogenomic profiling of cancer cell line panels

(2016) Peter M. Haverty et al.   NATURE

Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs

(2016) Rebecca A. Jackson et al.   PHARMACOLOGY & THERAPEUTICS

Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer

(2016) Supipi Duffy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation

(2016) Christian J. Braun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM

(2016) Alan S. L. Wong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A global genetic interaction network maps a wiring diagram of cellular function

(2016) M. Costanzo et al.   SCIENCE

Hereditary cancer syndromes as model systems for chemopreventive agent development

(2016) Farzana L. Walcott et al.   SEMINARS IN ONCOLOGY

CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions

(2016) D. M. Munoz et al.   Cancer Discovery

Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting

(2016) A. J. Aguirre et al.   Cancer Discovery

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial

(2016) Tracy L. Stockley et al.   Genome Medicine

Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer

(2016) Petra ter Brugge et al.   JNCI-Journal of the National Cancer Institute

Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis

(2015) Sidi Chen et al.   CELL

High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities

(2015) Traver Hart et al.   CELL

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

(2015) R. Pagliarini et al.   EMBO REPORTS

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

(2015) T. A. Hopkins et al.   MOLECULAR CANCER RESEARCH

REV7 counteracts DNA double-strand break resection and affects PARP inhibition

(2015) Guotai Xu et al.   NATURE

Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex

(2015) Silvana Konermann et al.   NATURE

Massively parallel high-order combinatorial genetics in human cells

(2015) Alan S L Wong et al.   NATURE BIOTECHNOLOGY

High-throughput functional genomics using CRISPR–Cas9

(2015) Ophir Shalem et al.   NATURE REVIEWS GENETICS

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets

(2015) Jing Guo et al.   NUCLEIC ACIDS RESEARCH

Gene essentiality and synthetic lethality in haploid human cells

(2015) V. A. Blomen et al.   SCIENCE

Identification and characterization of essential genes in the human genome

(2015) T. Wang et al.   SCIENCE

Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations

(2015) Özgün Babur et al.   GENOME BIOLOGY

Predicting essential genes and synthetic lethality via influence propagation in signaling pathways of cancer cell fates

(2015) Fan Zhang et al.   Journal of Bioinformatics and Computational Biology

Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality

(2014) Livnat Jerby-Arnon et al.   CELL

Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation

(2014) Luke A. Gilbert et al.   CELL

Synthetic Cytotoxicity: Digenic Interactions with TEL1/ATM Mutations Reveal Sensitivity to Low Doses of Camptothecin

(2014) Xuesong Li et al.   GENETICS

Transcriptional Roles of PARP1 in Cancer

(2014) Matthew J. Schiewer et al.   MOLECULAR CANCER RESEARCH

Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease

(2014) Cem Kuscu et al.   NATURE BIOTECHNOLOGY

Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector

(2014) Ami M. Kabadi et al.   NUCLEIC ACIDS RESEARCH

Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors

(2014) Y. Bian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers

(2014) G. R. Hoffman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system

(2014) Tetsushi Sakuma et al.   Scientific Reports

Genetic Interaction Networks: Toward an Understanding of Heritability

(2013) Anastasia Baryshnikova et al.   Annual Review of Genomics and Human Genetics

Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

(2013) Lei S. Qi et al.   CELL

CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes

(2013) Luke A. Gilbert et al.   CELL

Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens

(2013) Bhavneet Bhinder et al.   COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Poly(ADP-ribose): PARadigms and PARadoxes

(2013) Alexander Bürkle et al.   MOLECULAR ASPECTS OF MEDICINE

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

(2013) J. Murai et al.   MOLECULAR CANCER THERAPEUTICS

Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition

(2013) M. L. Bailey et al.   MOLECULAR CANCER THERAPEUTICS

A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities

(2013) F. J. Vizeacoumar et al.   Molecular Systems Biology

Inconsistency in large pharmacogenomic studies

(2013) Benjamin Haibe-Kains et al.   NATURE

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

RNA-Guided Human Genome Engineering via Cas9

(2013) P. Mali et al.   SCIENCE

Multiplex Genome Engineering Using CRISPR/Cas Systems

(2013) L. Cong et al.   SCIENCE

Systematic Triple-Mutant Analysis Uncovers Functional Connectivity between Pathways Involved in Chromosome Regulation

(2013) James E. Haber et al.   Cell Reports

RNA-programmed genome editing in human cells

(2013) Martin Jinek et al.   eLife

Genetic interaction networks: better understand to better predict

(2013) Benjamin Boucher et al.   Frontiers in Genetics

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

(2012) Louise J Barber et al.   JOURNAL OF PATHOLOGY

Hierarchical Modularity and the Evolution of Genetic Interactomes across Species

(2012) Colm J. Ryan et al.   MOLECULAR CELL

Dissection of DNA Damage Responses Using Multiconditional Genetic Interaction Maps

(2012) Aude Guénolé et al.   MOLECULAR CELL

A bioinformatics method identifies prominent off-targeted transcripts in RNAi screens

(2012) Frederic D Sigoillot et al.   NATURE METHODS

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

siRNA off-target effects in genome-wide screens identify signaling pathway members

(2012) Eugen Buehler et al.   Scientific Reports

Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators

(2012) Jessica L. McLellan et al.   PLoS Genetics

Drosophilacancer models

(2011) Vivek A. Rudrapatna et al.   DEVELOPMENTAL DYNAMICS

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay

(2011) Christof Fellmann et al.   MOLECULAR CELL

The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

(2011) Thomas Helleday   Molecular Oncology

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer

(2011) H. W. Cheung et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment

(2010) N. Chan et al.   CANCER RESEARCH

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

Rewiring of Genetic Networks in Response to DNA Damage

(2010) S. Bandyopadhyay et al.   SCIENCE

Rapid creation and quantitative monitoring of high coverage shRNA libraries

(2009) Michael C Bassik et al.   NATURE METHODS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing

(2009) K. J. McManus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

(2008) S. Rottenberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Conservation and Rewiring of Functional Modules Revealed by an Epistasis Map in Fission Yeast

(2008) A. Roguev et al.   SCIENCE